1
|
Pavel V, Räth U, Schmid S, Krautbauer S, Keller D, Amend P, Müller M, Mester P, Buechler C. Serum Adiponectin Predicts COVID-19 Severity. Biomedicines 2024; 12:1043. [PMID: 38791005 PMCID: PMC11117573 DOI: 10.3390/biomedicines12051043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2024] [Revised: 05/02/2024] [Accepted: 05/08/2024] [Indexed: 05/26/2024] Open
Abstract
Adiponectin is primarily known for its protective role in metabolic diseases, and it also possesses immunoregulatory properties. Elevated levels of adiponectin have been observed in various inflammatory diseases. However, studies investigating adiponectin levels in the serum of COVID-19 patients have yielded conflicting results. This study aimed to assess serum adiponectin levels in 26 healthy controls, as well as in 64 patients with moderate and 60 patients with severe COVID-19, to determine a potential association between serum adiponectin and the severity of COVID-19. Serum adiponectin levels in severe COVID-19 patients were significantly lower than in those with moderate disease and healthy controls, who exhibited similar serum adiponectin levels. Among patients with moderate disease, positive correlations were observed between serum adiponectin and C-reactive protein levels. Of note, serum adiponectin levels of severe COVID-19 cases were comparable between patients with and without dialysis or vasopressor therapy. Superinfection with bacteria did not exert a notable influence on serum adiponectin levels in patients with severe disease. Patients who were diagnosed with severe COVID-19 and vancomycin-resistant enterococci bacteremia showed a significant reduction in their serum adiponectin levels. An analysis conducted on the entire cohort, including both moderate and severe COVID-19 patients, showed that individuals who did not survive had lower serum adiponectin levels when compared to those who survived. In summary, this study highlights a decrease in serum adiponectin levels in severe COVID-19 cases, indicating the potential utility of adiponectin as an additional biomarker for monitoring disease severity in COVID-19 or critical illnesses in general.
Collapse
Affiliation(s)
- Vlad Pavel
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany; (V.P.); (U.R.); (S.S.); (D.K.); (P.A.); (M.M.); (P.M.)
| | - Ulrich Räth
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany; (V.P.); (U.R.); (S.S.); (D.K.); (P.A.); (M.M.); (P.M.)
| | - Stephan Schmid
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany; (V.P.); (U.R.); (S.S.); (D.K.); (P.A.); (M.M.); (P.M.)
| | - Sabrina Krautbauer
- Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053 Regensburg, Germany;
| | - Dennis Keller
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany; (V.P.); (U.R.); (S.S.); (D.K.); (P.A.); (M.M.); (P.M.)
| | - Pablo Amend
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany; (V.P.); (U.R.); (S.S.); (D.K.); (P.A.); (M.M.); (P.M.)
| | - Martina Müller
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany; (V.P.); (U.R.); (S.S.); (D.K.); (P.A.); (M.M.); (P.M.)
| | - Patricia Mester
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany; (V.P.); (U.R.); (S.S.); (D.K.); (P.A.); (M.M.); (P.M.)
| | - Christa Buechler
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany; (V.P.); (U.R.); (S.S.); (D.K.); (P.A.); (M.M.); (P.M.)
| |
Collapse
|
2
|
Oka T, Kouda K, Okada N, Saisyo A, Kashibe K, Hirano Y, Hiraki S, Yamasaki H, Ishida H, Kitahara T. A low prognostic nutritional index is associated with increased remote infections within 30 days of colorectal surgery: A retrospective cohort study. Am J Infect Control 2023; 51:1218-1224. [PMID: 37075854 DOI: 10.1016/j.ajic.2023.04.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 04/12/2023] [Accepted: 04/12/2023] [Indexed: 04/21/2023]
Abstract
OBJECTIVE This study aimed to identify risk factors for remote infection (RI) within 30 days after colorectal surgery. METHODS This retrospective study included 660 patients who underwent colorectal surgery at Yamaguchi University Hospital or Ube Kosan Central Hospital between April 2015 and March 2019. Using electronic medical records, we identified the incidence of surgical site infection and RI within 30 days after surgery and obtained information on associated factors. Univariate and multivariable analyses were performed to identify significant risk factors in 607 (median age, 71 years) patients. RESULTS Seventy-eight (13%) and 38 (6.3%) patients had surgical site infection and RI, respectively. Of the 38 patients diagnosed with RI, 14 (36.8%) had a bloodstream infection, 13 (34.2%) had a urinary tract infection, 8 (21.1%) had a Clostridioides difficile infection, and 7 (18.4%) had respiratory tract infections. Multivariable analysis showed that a preoperative prognostic nutritional index of ≤40 (OR, 2.30; 95% CI, 1.07-4.92; P = .032), intraoperative blood transfusion (OR (odds ratio), 3.06; 95% CI, 1.25-7.47; P = .014), and concomitant stoma creation (OR, 4.13; 95% CI, 1.93-8.83; P = .0002) were significant RI predictors. CONCLUSIONS Nutritional interventions prompted by low preoperative prognostic nutritional index in colorectal surgery may lead to decreases in postoperative RI.
Collapse
Affiliation(s)
- Tomoyuki Oka
- Pharmacy Department, Ube-Kohsan Central Hospital, Ube, Yamaguchi, Japan; Clinical Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
| | - Kyoji Kouda
- Pharmacy Department, Hofu Institute of Gastroenterology, Hofu, Yamaguchi, Japan
| | - Naoto Okada
- Pharmacy Department, Yamaguchi University Hospital, Ube, Yamaguchi, Japan
| | - Atsuyuki Saisyo
- Pharmacy Department, Yamaguchi University Hospital, Ube, Yamaguchi, Japan
| | - Kouichi Kashibe
- Medical Informatics and Decision Sciences, Yamaguchi University Hospital, Ube, Yamaguchi, Japan
| | - Yasushi Hirano
- Medical Informatics and Decision Sciences, Yamaguchi University Hospital, Ube, Yamaguchi, Japan
| | - Sakurao Hiraki
- Department of Surgery, Ube-Kohsan Central Hospital, Ube, Yamaguchi, Japan
| | - Hirofumi Yamasaki
- Pharmacy Department, Ube-Kohsan Central Hospital, Ube, Yamaguchi, Japan
| | - Haku Ishida
- Medical Informatics and Decision Sciences, Yamaguchi University Hospital, Ube, Yamaguchi, Japan
| | - Takashi Kitahara
- Pharmacy Department, Yamaguchi University Hospital, Ube, Yamaguchi, Japan; Clinical Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
| |
Collapse
|
3
|
Inoue Y, Ishii M, Fujii K, Nihei K, Suzuki Y, Ota M, Kitada K, Kuramoto T, Shima T, Kodama H, Matsuo K, Miyaoka Y, Miyamoto T, Yokohama K, Ohama H, Imai Y, Tanaka R, Sanda M, Osumi W, Tsuchimoto Y, Terazawa T, Ogura T, Masubuchi S, Yamamoto M, Asai A, Shirai Y, Inoue M, Fukunishi S, Nakahata Y, Takii M, Goto M, Kimura F, Higuchi K, Uchiyama K. Safety and Efficacy of Laparoscopic Liver Resection for Colorectal Liver Metastasis With Obesity. Am Surg 2020; 87:919-926. [PMID: 33283542 DOI: 10.1177/0003134820952448] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
INTRODUCTION Laparoscopic liver resection (LLR) in obese patients has been reported to be particularly challenging owing to technical difficulties and various comorbidities. METHODS The safety and efficacy outcomes in 314 patients who underwent laparoscopic or open nonanatomical liver resection for colorectal liver metastases (CRLM) were analyzed retrospectively with respect to the patients' body mass index (BMI) and visceral fat area (VFA). RESULTS Two hundred and four patients underwent LLR, and 110 patients underwent open liver resection (OLR). The rate of conversion from LLR to OLR was 4.4%, with no significant difference between the BMI and VFA groups (P = .647 and .136, respectively). In addition, there were no significant differences in terms of operative time and estimated blood loss in LLR (P = .226 and .368; .772 and .489, respectively). The incidence of Clavien-Dindo grade IIIa or higher complications was not significantly different between the BMI and VFA groups of LLR (P = .877 and .726, respectively). In obese patients, the operative time and estimated blood loss were significantly shorter and lower, respectively, in LLR than in OLR (P = .003 and < .001; < .001 and < .001, respectively). There was a significant difference in the incidence of postoperative complications, organ/space surgical site infections, and postoperative bile leakage between the LLR and OLR groups (P = .017, < .001, and < .001, respectively). CONCLUSION LLR for obese patients with CRLM can be performed safely using various surgical devices with no major difference in outcomes compared to those in nonobese patients. Moreover, LLR has better safety outcomes than OLR in obese patients.
Collapse
Affiliation(s)
- Yoshihiro Inoue
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan.,Department of General and Gastroenterological Surgery, Osaka Medical College Mishima-Minami Hospital, Japan
| | - Masatsugu Ishii
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan.,Department of General and Gastroenterological Surgery, Osaka Medical College Mishima-Minami Hospital, Japan
| | - Kensuke Fujii
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| | - Kentaro Nihei
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| | - Yusuke Suzuki
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| | - Masato Ota
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| | - Kazuya Kitada
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| | - Toru Kuramoto
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| | - Takafumi Shima
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| | - Hiroyuki Kodama
- Second Department of Internal Medicine, Osaka Medical College Hospital, Japan
| | - Kentaro Matsuo
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan.,Department of General and Gastroenterological Surgery, Osaka Medical College Mishima-Minami Hospital, Japan
| | - Yuta Miyaoka
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan.,Department of General and Gastroenterological Surgery, Osaka Medical College Mishima-Minami Hospital, Japan
| | - Takahiro Miyamoto
- Second Department of Internal Medicine, Osaka Medical College Hospital, Japan
| | - Keisuke Yokohama
- Second Department of Internal Medicine, Osaka Medical College Hospital, Japan
| | - Hideko Ohama
- Second Department of Internal Medicine, Osaka Medical College Hospital, Japan
| | - Yoshiro Imai
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| | - Ryo Tanaka
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| | - Mariko Sanda
- Department of Internal Medicine, Osaka Medical College Mishima-Minami Hospital, Japan
| | - Wataru Osumi
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| | - Yusuke Tsuchimoto
- Second Department of Internal Medicine, Osaka Medical College Hospital, Japan
| | - Tetsuji Terazawa
- Second Department of Internal Medicine, Osaka Medical College Hospital, Japan
| | - Takeshi Ogura
- Second Department of Internal Medicine, Osaka Medical College Hospital, Japan
| | - Shinsuke Masubuchi
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| | - Masashi Yamamoto
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan.,Department of General and Gastroenterological Surgery, Osaka Medical College Mishima-Minami Hospital, Japan
| | - Akira Asai
- Second Department of Internal Medicine, Osaka Medical College Hospital, Japan
| | | | - Masaya Inoue
- Department of Surgery, Katsuragi Hospital, Japan
| | - Shinya Fukunishi
- Second Department of Internal Medicine, Osaka Medical College Hospital, Japan
| | - Yoshikatsu Nakahata
- Department of Internal Medicine, Osaka Medical College Mishima-Minami Hospital, Japan
| | - Michiaki Takii
- Department of Internal Medicine, Osaka Medical College Mishima-Minami Hospital, Japan
| | - Masahiro Goto
- Second Department of Internal Medicine, Osaka Medical College Hospital, Japan
| | - Fumiharu Kimura
- Department of Internal Medicine, Osaka Medical College Mishima-Minami Hospital, Japan
| | - Kazuhide Higuchi
- Second Department of Internal Medicine, Osaka Medical College Hospital, Japan
| | - Kazuhisa Uchiyama
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Japan
| |
Collapse
|
4
|
Akabori H, Tani M, Kitamura N, Maehira H, Imashuku Y, Tsujita Y, Shimizu T, Kitagawa H, Eguchi Y. Perioperative tight glycemic control using artificial pancreas decreases infectious complications via suppression of inflammatory cytokines in patients who underwent pancreaticoduodenectomy: A prospective, non-randomized clinical trial. Am J Surg 2019; 220:365-371. [PMID: 31836178 DOI: 10.1016/j.amjsurg.2019.12.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 11/25/2019] [Accepted: 12/03/2019] [Indexed: 01/03/2023]
Abstract
BACKGROUND We sought to investigate the efficacy of perioperative tight glycemic control (TGC) in reducing of postoperative infectious complications (POICs) and study its impact on early inflammatory mediators in patients who underwent pancreaticoduodenectomy. METHODS In this non-randomized trial, the artificial pancreas (AP) group received TGC (target glucose range of 80-110 mg/dL; n = 14), while the control group received conventional glycemic control (range of 80-180 mg/dL; n = 15). The primary endpoint was POICs. RESULTS The AP group had a markedly decreased POIC rate (28.6% vs. 73.3%; P = 0.027), mean glycemic variability (13.5 ± 3.5% vs. 16.4 ± 5.9%; P = 0.038), and plasma interleukin-6 level (26.3 ± 33.8 vs 98.3 ± 89.1 pg/ml; P = 0.036) compared to the control group, but insulin dosage (27.0 ± 13.4 vs. 10.2 ± 16.2 U; P = 0.002) and the adiponectin ratio (i.e., postoperative/preoperative adiponectin; 0.8 ± 0.2 vs. 0.6 ± 0.3; P = 0.021) were markedly higher in the AP group. CONCLUSIONS Among patients undergoing PD with impaired glucose tolerance, AP facilitated strict glycemic control and resulted in a reduction of anti-inflammatory mediators and POICs. SUMMARY Perioperative hyperglycemia increases postoperative infectious complications; however, tight glycemic control using artificial pancreas can reduce them via a dual effect. Artificial pancreas facilitates strict and safe glycemic control while reducing anti-inflammatory mediators, including adiponectin, following pancreaticoduodenectomy.
Collapse
Affiliation(s)
| | | | | | | | | | - Yasuyuki Tsujita
- Department of Critical and Intensive Care Medicine, Shiga University of Medical Science, Shiga, Japan
| | | | | | - Yutaka Eguchi
- Department of Critical and Intensive Care Medicine, Shiga University of Medical Science, Shiga, Japan
| |
Collapse
|
5
|
Mahdi BM. Significant of adiponectin in gastropathy: Case-controlled study. Ann Med Surg (Lond) 2019; 47:16-18. [PMID: 31641495 PMCID: PMC6796547 DOI: 10.1016/j.amsu.2019.09.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Revised: 09/06/2019] [Accepted: 09/16/2019] [Indexed: 12/17/2022] Open
Abstract
Background Gastropathy is a medical broad term applied for stomach diseases that affect mucosal lining characterized by epithelial injury. There are many types of gastropathy ranging from harmless conditions to more serious ones like cancer. Aim of the study to assess the significant effect of adiponectin and its level in patients with gastropathy. Patients and methods This case-control study includes 35 patients with gastropathy confirmed by gastroscope and thirty control group. Anthropometric Measurements like Weight, height, waist circumference, body mass index, and waist circumference. Blood sample was collected from the patients and control group and serum tested for lipid profile that includes (cholesterol, triglyceride, HDLP, LDLP) (Human-Germany), and adiponectin (Shanghai Biologic Technology-China) using Enzyme-Linked Immunosorbent Assay (ELISA). Results There is a significant difference between the two groups regarding height, weight, waist circumference, and waist to hip ratio (P-value 0.002,0.009, 0.002 and 0.015 respectively). Regarding adiponectin, there is no significant difference between patients (9.54 ± 5.821 and control 9.119 ± 7.062)(P = 0.796). Lipid profile showed a significant increase in cholesterol (p = 0.0001) and triglyceride (0.007) in patients group while there is no significant difference in HDL, LDL and LDL/HDL ratio. Conclusions Adiponectin had no role in the development of gastropathy. Patients with gastropathy had a significant increase in the serum level of cholesterol and triglyceride. There is a significant negative correlation between adiponectin and weight, body mass index, waist circumference, triglyceride, and low-density lipoprotein. Gastropathy is a medical broad term applied for stomach diseases. Effect of adiponectin and its level in patients with gastropathy. This case-control study includes 35 patients with gastropathy confirmed by gastroscope and thirty control group. Anthropometric Measurements and blood sample were collected from two groups. There is a significant difference between two groups regarding height, weight, waist circumference and waist to hip ratio while adiponectin there is no significant difference between two groups.
Collapse
Affiliation(s)
- Batool Mutar Mahdi
- Head of HLA Research Unit, Department of Microbiology, Al-Kindy College of Medicine, University of Baghdad, Iraq
| |
Collapse
|
6
|
Quan H, Zhang H, Wei W, Fang T, Chen D, Chen K. A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus. Exp Ther Med 2017; 14:3279-3287. [PMID: 28912879 DOI: 10.3892/etm.2017.4863] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2015] [Accepted: 11/18/2016] [Indexed: 12/27/2022] Open
Abstract
The aim of the present study was to explore the effects of various combinations of exenatide, metformin (MET) and biphasic insulin aspart 30 (BIA30) on type 2 diabetes mellitus (T2DM). Two hundred overweight or obese patients newly diagnosed with T2DM were evenly randomized into two groups: A (twice daily for all: Phase I, 5 µg exenatide + 0.5 g MET for 4 weeks, then 10 µg exenatide + 0.5 g MET for 8 weeks; Phase II, 0.5 g MET for 12 weeks; Phase III, 0.3-0.4 U/kg/day BIA30 + 0.5 g MET for 12 weeks) and B (Phases I, II, III matched the phases III, II and I in group A). In groups A and B a significant decrease and increase, respectively, in glycated hemoglobin (HbAlc) and body mass index (BMI) was noted during Phase I. A 3.2±0.4-kg decrease in body weight in group A and a 2.6±0.3-kg increase in group B was observed. In Phase II, HbAlc was significantly increased in both groups (P<0.05). In Phase III, the BMI was increased in group A and reduced in group B (P<0.05). There was a 3.8±0.4-kg weight decrease in group B and 4.2±0.5-kg increase in group A (P<0.05). The combination of exenatide and MET promoted weight loss, glycemic control, β-cell function index, C peptide and adiponectin levels. These results suggested that the combination of exenatide and MET is better than the combination of BIA and MET for the therapy of overweight or obese patients newly diagnosed with T2DM.
Collapse
Affiliation(s)
- Huibiao Quan
- Department of Endocrinology, People's Hospital of Hainan, Haikou, Hainan 570311, P.R. China
| | - Huachuan Zhang
- Department of Endocrinology, People's Hospital of Hainan, Haikou, Hainan 570311, P.R. China
| | - Weiping Wei
- Department of Endocrinology, People's Hospital of Hainan, Haikou, Hainan 570311, P.R. China
| | - Tuanyu Fang
- Department of Endocrinology, People's Hospital of Hainan, Haikou, Hainan 570311, P.R. China
| | - Daoxiong Chen
- Department of Endocrinology, People's Hospital of Hainan, Haikou, Hainan 570311, P.R. China
| | - Kaining Chen
- Department of Endocrinology, People's Hospital of Hainan, Haikou, Hainan 570311, P.R. China
| |
Collapse
|
7
|
Zhao L, Sun T, Wang L. Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus. Ther Clin Risk Manag 2017; 13:739-750. [PMID: 28721055 PMCID: PMC5499789 DOI: 10.2147/tcrm.s134039] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Sitagliptin improves glycemic control in type 2 diabetes mellitus (T2DM) patients but its side effects are undesirable. Chitosan oligosaccharide (COS) is expected to improve the therapeutic result as a natural product. A total of 200 elderly T2DM patients were evenly assigned into four groups: sitagliptin group (SG), receiving sitagliptin 100 mg/day; COS group (CG), receiving COS 100 mg/day; combination therapy of sitagliptin and COS group (SCG), receiving both sitagliptin and COS 100 mg/day; and placebo group (PG), receiving placebo 100 mg/day. After 42-week therapy, biochemical indices and clinical parameters for the alterations from start points were analyzed. The related molecular mechanism was tested by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot at cell level. Lower risk of hypoglycemia was found in the SCG group when compared with SG and other groups (P<0.05). More patients from the SCG group than other groups attained hemoglobin A1c (HbA1c) reduction >2.5% (P<0.05). Weight reduction of 1.2±0.9, 2.6±0.8, 4.7±1.3, and 0.9±0.6 kg was observed in the patients from SG, CG, SCG, and PG groups, respectively (P<0.05). The combined treatment of COS and sitagliptin presented better therapeutic results by improving insulin sensitivity, lipid profile, adiponectin levels, and glucagon-like peptide 1 and reducing side effects, insulin resistance, HbA1c, body mass index, resistin, tumor necrosis factor (TNF)-α, and C-reactive protein (CRP) (P<0.05). qRT-PCR and Western blot analysis also showed that COS treatment reduced the levels of resistin, TNF-α, and CRP, and increased the level of adiponectin. The combination of COS and sitagliptin provided better glycemic control with fewer side effects and with more weight reduction in the elderly participants with T2DM.
Collapse
Affiliation(s)
| | - Tingli Sun
- Department of Nephrology, General Hospital of Daqing Oil Field, Daqing, China
| | | |
Collapse
|
8
|
Yamamoto H, Maeda K, Arima H, Sonoda H, Shimizu T, Mekata E, Kaida S, Yamaguchi T, Murata S, Miura K, Kadowaki M, Tani M. Perioperative Adiponectin Measurement is Useful for Prediction of Postoperative Infection in Patients with Colorectal Cancer. Ann Surg Oncol 2016; 23:540-545. [PMID: 27364509 DOI: 10.1245/s10434-016-5386-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Indexed: 11/18/2022]
Abstract
BACKGROUND Adiponectin (ADN) is a key molecule associated with obesity and metabolic syndrome, and functions as an immunomodulator. We have shown that the ADN ratio (i.e., postoperative ADN/preoperative ADN) can predict infection after gastrectomy in patients with gastric cancer . In the present study, we evaluated whether the ADN ratio could reliably predict the incidence of postoperative infection in patients undergoing colorectal cancer surgery. METHODS We retrospectively analyzed 131 consecutive patients who underwent colorectal cancer surgery and measured their preoperative and postoperative ADN values. The outcome was postoperative infection, including surgical site and remote infections. The association between the ADN ratio and postoperative infection was assessed using logistic regression models. For the ADN ratio and other significant predictors, we conducted receiver operating characteristics (ROC) analyses. RESULTS Forty-nine patients (37.4 %) experienced postoperative infections. Logistic regression analysis indicated that the ADN ratio was most significantly associated with postoperative infection [odds ratio per one standard deviation (1 SD) decrease 0.36; 95 % confidence interval 0.18-0.71] even after adjustment for diabetes, type of surgery, blood loss, C-reactive protein level, and preoperative ADN level. History of type 2 diabetes mellitus also significantly predicted postoperative infection (odds ratio per 1 SD increase 2.93; 95 % confidence interval 1.03-8.38). When predicting postoperative infection, the area under the ROC curve for the ADN ratio (0.707) was comparable to that for blood loss (0.698; p = 0.975). CONCLUSIONS ADN ratio is a clinically useful predictor of postoperative infection in patients undergoing colorectal cancer.
Collapse
Affiliation(s)
- Hiroshi Yamamoto
- Department of Surgery, Shiga University of Medical Science, Shiga, Japan.
| | - Kazuhisa Maeda
- Department of Metabolic Medicine, Osaka University Hospital, Osaka, Japan
| | - Hisatomi Arima
- Department of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Hiromichi Sonoda
- Department of Surgery, Shiga University of Medical Science, Shiga, Japan
| | - Tomoharu Shimizu
- Department of Surgery, Shiga University of Medical Science, Shiga, Japan
| | - Eiji Mekata
- Department of Comprehensive Surgery, Shiga University of Medical Science, Shiga, Japan
| | - Sachiko Kaida
- Department of Surgery, Shiga University of Medical Science, Shiga, Japan
| | - Tsuyoshi Yamaguchi
- Department of Surgery, Shiga University of Medical Science, Shiga, Japan
| | - Satoshi Murata
- Department of Surgery, Shiga University of Medical Science, Shiga, Japan
| | - Katsuyuki Miura
- Department of Public Health, Shiga University of Medical Science, Shiga, Japan.,Center for Epidemiologic Research in Asia, Shiga University of Medical Science, Shiga, Japan
| | - Makoto Kadowaki
- Division of Gastrointestinal Pathophysiology, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama, Japan
| | - Masaji Tani
- Department of Surgery, Shiga University of Medical Science, Shiga, Japan
| |
Collapse
|
9
|
Yamamoto H, Nakae H, Uji Y, Maeda K, Tani T, Eguchi Y. Plasma Adiponectin Levels in Acute Liver Failure Patients Treated with Plasma Filtration with Dialysis and Plasma Exchange. Ther Apher Dial 2016; 19:349-54. [PMID: 26386223 DOI: 10.1111/1744-9987.12344] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Plasma filtration with dialysis (PDF) is a blood purification therapy in which simple plasma exchange (PE) is performed using a selective membrane plasma separator while the dialysate flows outside of the hollow fibers. Improvement of hypoadiponectinemia is considered to be a useful therapeutic approach for ameliorating fatal conditions including cardio-metabolic and infectious disease. We investigated the effects of PDF in comparison to PE in terms of plasma adiponectin (APN) changes in patients with acute liver failure. Seventeen patients with liver failure were studied; PDF was performed 55 times and PE 14 times. Plasma APN levels increased significantly after PDF, while decreasing significantly after PE. PDF appears to be among the most useful blood purification therapies in acute liver failure cases in terms of increasing APN levels.
Collapse
Affiliation(s)
- Hiroshi Yamamoto
- Department of Surgery, Shiga University of Medical Science, Shiga, Japan
| | - Hajime Nakae
- Department of Emergency and Critical Care Medicine, Akita University School of Medicine, Akita, Japan
| | - Yoshitaka Uji
- Department of Gastroenterological Surgery, Shinkoga Hospital, Fukuoka, Japan
| | - Kazuhisa Maeda
- Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Tohru Tani
- Department of Surgery, Shiga University of Medical Science, Shiga, Japan
| | - Yutaka Eguchi
- Department of Critical and Intensive Care Medicine, Shiga University of Medical Science, Shiga, Japan
| |
Collapse
|
10
|
Sharma G, Kulkarni R, Shah SK, King WW, Longchamp A, Tao M, Ding K, Ozaki CK. Local perivascular adiponectin associates with lower extremity vascular operative wound complications. Surgery 2016; 160:204-210. [PMID: 27085683 DOI: 10.1016/j.surg.2016.01.024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Revised: 01/08/2016] [Accepted: 01/16/2016] [Indexed: 01/31/2023]
Abstract
BACKGROUND Wound complication rates after lower extremity vascular operative procedures stand as high as 40% and represent a major cause of morbidity, mortality, and cost. In view of increasing recognition of adipose tissue involvement in homeostasis and the response to injury, we hypothesized that adipose phenotype is linked to operative wound outcomes. METHODS Clinical history, peripheral blood, and subcutaneous and perivascular adipose tissue were prospectively collected at the time of operation in patients undergoing lower extremity revascularization and lower extremity amputations. Nine biologic mediators (adiponectin; interleukin [IL]-1β, IL-6, and IL-8; leptin; monocyte chemoattractant protein-1; plasminogen activator inhibitor-1; resistin; and tumor necrosis factor) were assayed in the adipose tissues and plasma. The 30-day wound complications were captured in real time. Logarithmic transformation of mediator levels was performed based on positively skewed, non-Gaussian distribution, and data were compared using the Student t test. Bonferroni correction was used for multiple comparisons. RESULTS Sixty-six patients undergoing lower extremity revascularization or lower extremity amputations for severe peripheral arterial disease were enrolled. The 30-day follow-up was 92.4%. In total, 19 (29%) patients developed wound complications. Patients who developed wound complications had elevated perivascular adiponectin levels (mean ± standard error, 2,372.45 ± 648.64 ng/mL vs 832.53 ± 180.54 ng/mL, P = .004). Perivascular IL-1β levels were lower among patients with wound dehiscence (0.41 ± 0.004 pg/mL vs 0.73 ± 0.09 pg/mL, P = .001). CONCLUSION Local adipose tissue mediator levels at the time of operation demonstrate a previously undescribed compartment-specific relationship to wound outcomes in patients undergoing lower extremity vascular operative procedures. These associations provide fertile directives for defining the mechanisms underlying the pathogenesis of wound complications and their prevention.
Collapse
Affiliation(s)
- Gaurav Sharma
- Department of Surgery, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
| | - Rohan Kulkarni
- Department of Surgery, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
| | - Samir K Shah
- Department of Surgery, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
| | - William W King
- Department of Surgery, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
| | - Alban Longchamp
- Department of Surgery, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
| | - Ming Tao
- Department of Surgery, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
| | - Kui Ding
- Department of Surgery, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
| | - C Keith Ozaki
- Department of Surgery, Brigham and Women's Hospital/Harvard Medical School, Boston, MA.
| |
Collapse
|
11
|
Gao Q, Zheng J. Adiponectin-induced antitumor activity on prostatic cancers through inhibiting proliferation. Cell Biochem Biophys 2015; 70:461-5. [PMID: 24793551 DOI: 10.1007/s12013-014-9941-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Adiponectin, an adipose tissue-derived hormone, has been studied intensively for the past decade because of its anti-inflammatory, anti-atherogenic, and anti-diabetic properties. Recent advances suggest that adiponectin also plays an important role in the development and progression of various cancers. Accumulating evidence suggests that adiponectin may have an important protective role in carcinogenesis. Adiponectin circulates at high concentrations in human plasma. Plasma levels of adiponectin are approximately 50 % lower in obese than in lean subjects. An association between low plasma levels of adiponectin and higher risk of developing prostate and other cancers was recently reported. Obesity and overweight have also been associated with increased mortality from cancer. To test the hypothesis that adiponectin exerts direct antiproliferative and/or pro-apoptotic effects on cancer cells, we used the PC-3 human prostate adenocarcinoma cell line. The proliferation rate of the PC-3 cells was measured using the MTT method, and apoptosis was examined by quantifying the DNA fragmentation using an ELISA assay. In addition, adiponectin receptor 1 (AdipoR1) and AdipoR2 mRNA expression was detected using RT-PCR. Adiponectin diminished the proliferation rate of PC-3 cells; this effect was significant after 48-96 h of treatment. The presence of receptor expression suggested that the effect of adiponectin on cell proliferation was most likely specific and adiponectin receptor-mediated. Adiponectin induced no apoptosis of PC-3 cells over 48 h. We conclude that adiponectin inhibits proliferation but causes no apoptosis of PC-3 prostate cancer cells.
Collapse
Affiliation(s)
- Qiruo Gao
- Department of Urology, Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai, China
| | | |
Collapse
|
12
|
Ortega-Deballon P, Ménégaut L, Fournel I, Orry D, Masson D, Binquet C, Facy O. Are Adiponectin and Leptin Good Predictors of Surgical Infection after Colorectal Surgery? A Prospective Study. Surg Infect (Larchmt) 2015; 16:566-71. [PMID: 26114869 DOI: 10.1089/sur.2014.206] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND Infections are the most frequent complication after colorectal surgery. It has been suggested that adipose tissue metabolism could be related to the risk of post-operative infection, but this could be partially related to the body-mass index. The aim of this study was to look for a relation between adipocytokine levels and the risk of post-operative infection and its type. METHODS This prospective cohort study was conducted between March 2013 and March 2014 in two French teaching hospitals. Pre-operative plasma levels of adiponectin and leptin were measured in consecutive patients undergoing elective colorectal surgery. All infections in the 30 d following surgery were recorded. RESULTS Among the 142 patients included, 29 (20.4%) presented a post-operative infection: 26 surgical site infections and three extra-abdominal infections. Adiponectin and leptin levels correlated weakly but substantially with the body mass index (rspearman=-0.26 and +0.31, respectively). While there was no substantial difference between patients with and those without post-operative infection for adiponectin, median pre-operative leptin was substantially greater in patients with post-operative infection (8.67 vs. 4.37 ng/mL, p=0.003). A substantial interaction was found between leptin and cancer. In patients operated on for cancer, the area under the receiver-operating characteristic (ROC) curve was lower than in patients with benign diseases (0.597 vs. 0.858, p=0.011). Similar results were observed for intra-abdominal infection and surgical site infection. CONCLUSION Patients with greater levels of leptin before colorectal surgery have an increased risk of post-operative surgical infection. This effect is stronger in patients without cancer. Adiponectin levels are not related to the risk of infection in Western patients.
Collapse
Affiliation(s)
- Pablo Ortega-Deballon
- 1 Department of Digestive Surgery, Clinical Epidemiology/Clinical Trials, University Hospital of Dijon , Dijon, France .,4 INSERM, U866, Dijon, France; University of Burgundy , School of Health, Dijon, France
| | - Louise Ménégaut
- 2 Department of Biochemistry, Clinical Epidemiology/Clinical Trials, University Hospital of Dijon , Dijon, France
| | - Isabelle Fournel
- 3 Department of Clinical Investigation Centre, Clinical Epidemiology/Clinical Trials, University Hospital of Dijon , Dijon, France
| | - David Orry
- 5 Department of Surgical Oncology, Georges-François Leclerc Anticancer Centre , Dijon, France
| | - David Masson
- 2 Department of Biochemistry, Clinical Epidemiology/Clinical Trials, University Hospital of Dijon , Dijon, France .,4 INSERM, U866, Dijon, France; University of Burgundy , School of Health, Dijon, France
| | - Christine Binquet
- 3 Department of Clinical Investigation Centre, Clinical Epidemiology/Clinical Trials, University Hospital of Dijon , Dijon, France .,4 INSERM, U866, Dijon, France; University of Burgundy , School of Health, Dijon, France
| | - Olivier Facy
- 1 Department of Digestive Surgery, Clinical Epidemiology/Clinical Trials, University Hospital of Dijon , Dijon, France .,4 INSERM, U866, Dijon, France; University of Burgundy , School of Health, Dijon, France
| |
Collapse
|
13
|
Nagaraju GP, Aliya S, Alese OB. Role of adiponectin in obesity related gastrointestinal carcinogenesis. Cytokine Growth Factor Rev 2015; 26:83-93. [DOI: 10.1016/j.cytogfr.2014.06.007] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2014] [Revised: 05/18/2014] [Accepted: 06/16/2014] [Indexed: 12/15/2022]
|